GlassScriptPhysician profile
Bridget Haley Sykes
NPI 1821575879
$648.83
in general payments reported to CMS, 2019-2025
14 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.55 · 2023: $134 · 2024: $164 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $176.80 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $124.43 | 2022-2025 | |
| Janssen Biotech, INC. | $85.14 | 2022-2025 | Erleada |
| Pfizer INC. | $56.33 | 2023-2025 | |
| Daiichi Sankyo INC. | $34.85 | 2024 | Enhertu |
| Genzyme Corporation | $34.82 | 2025 | |
| Abbvie INC. | $28.47 | 2023 | |
| Rigel Pharmaceuticals, INC. | $17.80 | 2023 | Tavalisse, Rezlidhia |
| Array Biopharma INC | $16.28 | 2025 | Braftovi, Lorbrena, Mektovi |
| Celgene Corporation | $15.38 | 2023 | Reblozyl |
| Servier Pharmaceuticals LLC | $15.13 | 2025 | |
| Gilead Sciences, INC. | $15.01 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.93 | 2023 | Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $13.46 | 2025 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Sykes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.